Resources
About Us
Meticulous Research®—a leading market research company, published a research report titled, ‘Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated) Virus (Adenovirus, Retrovirus, Plasmid DNA, AAV), Approach, Indication, Application, Packaging—Global Forecast to 2031’
According to this latest publication from Meticulous Research®, the viral vaccines market is projected to reach $47.01 billion by 2031, at a CAGR of 1.9% from 2024 to 2031. The growth of the viral vaccines market is driven by the strong product pipeline for vaccines, increasing government focus on immunization programs, technological advancements in vaccine administration, use of inactivated vaccines in surgeries or treatment, and the capacity expansion of biopharmaceutical products. Moreover, the growing focus on therapeutic vaccines, increasing use of adjuvants in vaccines, growth prospects in emerging markets, and development of highly stable and energy-efficient ultra-low temperature freezers are expected to offer growth opportunities for the players operating in this market.
Key Players
The key players profiled in the viral vaccines market report are Pfizer, Inc. (U.S.), AstraZeneca plc (U.K.), GlaxoSmithKline plc (U.K.), Sanofi S.A. (Italy), CSL Ltd. (Australia), Mitsubishi Tanabe Pharma Corporation (Japan), Merck & Co., Inc. (U.S.), Moderna, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Dynavax Technologies Corporation (U.S.), Serum Institute of India Pvt. Ltd (India), Emergent BioSolutions, Inc. (U.S.), Bharat Biotech International Limited (BBIL) (India), and Valneva SE (France).
The viral vaccines market is segmented by Form (Liquid Vaccines, Lyophilized Vaccines), Vaccine Type (Live-attenuated Vaccines, Inactivated Vaccines, mRNA Vaccines, Viral Vector Vaccines, Subunit & Conjugate Vaccines, Toxoid Vaccines, Combination Vaccines), Virus Type (Adenovirus, Retrovirus, Plasmid DNA, Adeno-associated Virus (AAV), Lentivirus, and Other Virus Types), Route of Administration (Intramuscular (IM), Subcutaneous (SC), Oral, and Other Routes of Administration), Approach (Preventive Vaccines, Therapeutic Vaccines), Indication (Infectious Diseases, Cancer, Genetic Disorders, and Other Indications), Application (Antisense Therapy, Gene Therapy, Cell Therapy, and Vaccinology), Packaging (Vials, Prefilled Syringes) and Geography. The study also evaluates industry competitors and analyzes the regional and country-level markets.
Among all forms studied in the report, in 2024, the liquid vaccines segment is expected to account for the largest share of the market. Liquid vaccines contain formulations in the liquid form which are easy to administer. The large market share of the segment is attributed to factors such as ease of administration, no reconstitution of vaccines needed, reduced risk of errors, simplified logistics as compared to lyophilized vaccines, decreased need for equipment and training requirements, lower contamination risks, growing prevalence of infectious diseases, and reduced wastage of vaccine accessories.
Among all vaccine types studied in the report, in 2024, the subunit & conjugate vaccines segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the absence of live components or microorganisms, precise targeting of pathogens, capability of eliciting a protective immune response, low risk of immunogenicity, and long-term immunity.
Among all virus types studied in the report, in 2024, the adenovirus segment is expected to account for the largest share of the market. The large share of this segment is attributed to efficient gene delivery, strong immune response, replication-incompetent viruses, and high scalability as compared to other virus types. Institutes, organizations, and companies have been collaborating to increase the number of immunizations for various infectious diseases. For instance, in January 2024, ReiThera Srl (Italy), the Ragon Institute of Mass General, MIT, and Harvard (U.S.), and the International AIDS Vaccine Initiative, Inc. (IAVI) (U.S.) announced a collaboration to develop a novel HIV vaccine candidate that comprises ReiThera’s GRAd vector and HIV T-cell epitopes. These organizations will perform vector engineering and generation, process development, good manufacturing practice (GMP), and preclinical development to evaluate the safety and immunogenicity of the GRAd-HIV vaccine for clinical use.
Among all approaches studied in the report, in 2024, the preventive vaccines segment is expected to account for the larger share of the market. Preventive vaccines are provided to people with the goal of not contracting infections due to viruses or bacteria. The large market share of this segment is attributed to the increasing prevalence of chronic and infectious diseases, rising awareness for immunization in public, growing immunization programs, induction of herd immunity, and the prevention of disease outbreaks.
Among all indications studied in the report, the infectious diseases segment is expected to account for the largest share of the market. The large growth of the segment is attributed to factors such as prevention of diseases, reduced morbidity and mortality rates, cost-effectiveness, global health security, increased herd immunity, long-term protection, and the increasing prevalence of infectious diseases. According to the World Health Organization (WHO), approximately 1.5 million children under the age of 5 lose their lives due to vaccine-preventable diseases every year. Various companies are manufacturing vaccines and therapeutics to reduce the number of fatalities due to infectious diseases. For instance, in October 2023, the R21/Matrix-M malarial vaccines developed by Oxford University (U.K.) and the Serum Institute of India Pvt Ltd. (India), using Novartis AG’s (Switzerland) adjuvant technology, was recommended by the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG)
Among all applications studied in the report, in 2024, the antisense therapy segment is expected to account for the largest share of the market. The large market share of this segment is attributed to factors such as the growing prevalence of infectious diseases, technological advancements in the use of viral vectors, and increasing healthcare expenditure. Antisense vaccines are capable of inducing both humoral (antibody-mediated) and cellular immune responses. This comprehensive immune response can protect against a wide range of pathogens and enhance vaccine efficacy, supporting their largest adoption.
Among all geographies, in 2024, North America is expected to account for the largest share of the market. The large share of this regional market is attributed to factors such as advanced research infrastructure in the region, the presence of key pharmaceutical companies, collaborations between research institutes and pharmaceutical companies, the establishment of new facilities in the region by key players, awareness for vaccination, and risk of emerging pandemics.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5920
Key questions answered in the report:
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researc
India VNA & PACS Market to Reach $341.6 Million by 2031
Read MoreChina Microarray Market to Be Worth $910.4 Million by 2031
Read MoreChina Neurogenomics Market to Reach $562.1 Million by 2031
Read MoreELISA Market to be Worth $32.69 Billion by 2031
Read MoreDNA Sequencing Market to be Worth $21.30 Billion by 2031
Read MoreOral Care Market to be Worth $58.99 Billion by 2031
Read MoreSpirometer Market to be Worth $1.80 Billion by 2031
Read MorePet Care Market to be Worth $287.96 Billion by 2031
Read MoreRegenerative Medicine Market to be Worth $37.27 Billion by 2031
Read MoreHemostats Market to be Worth $5.32 Billion by 2031
Read MoreBioreactors Market to be Worth $39.96 Billion by 2031
Read MoreProtein Assays Market to be Worth $4.36 Billion by 2031
Read MoreVeterinary API Market to Reach $15.84 Billion by 2031
Read MoreAsia-Pacific NGS Automation Market to be Worth $371 Million by 2031
Read MoreLatin America NGS Market to be Worth $765.2 Million by 2031
Read MoreBiochemical Reagents Market to be Worth $39.61 Billion by 2031
Read MoreMicroarray Kits Market to be Worth $2.51 Billion by 2031
Read MoreAntibody Production Market to Reach $58.35 Billion by 2031
Read MoreMiddle East IVD Market to be Worth $2.15 Billion by 2031
Read MoreSpatial Genomics Market to be Worth $3.23 Billion by 2031
Read MoreAsia-Pacific IVD Market to be Worth $36.02 Billion by 2031
Read MoreEurope NGS Market to be Worth $6.40 Billion by 2030
Read MoreLab Automation Market to be Worth $11.31 Billion by 2031
Read MoreBioinformatics Market to Reach $31.71 Billion by 2031
Read MoreEurope IVD Market to be Worth $39.77 Billion by 2030
Read MoreSequencing Kits Market to be Worth $25.29 Billion by 2031
Read MoreVeterinary API Market to Reach $15.84 Billion by 2031
Read MoreSample Preparation Market to be Worth $12.77 Billion by 2031
Read MoreSurgical Robots Market Worth $25.47 Billion by 2030
Read MoreMedical Coatings Market Worth $3.32 Billion by 2030
Read MoreLiquid Handling Systems Market Worth $6.99 Billion by 2029
Read MoreElectrosurgery Market to be Worth $8.99 Billion by 2031
Read MoreRadiation Dose Management Market Worth $749.1 Million by 2029
Read MoreMolecular Diagnostics Market Worth $46.69 Billion by 2030
Read MoreNewborn Screening Market to be Worth $2.69 Billion by 2031
Read MorePharmacogenomics Market to be Worth $19.5 Billion by 2031
Read MoreDental Practice Management Software Market Worth $ 3.11 Billion by 2029
Read MoreNepal IVD Market Worth $62.7 Million by 2029
Read MorePharmaceutical Contract Packaging Market Worth $42.03 Billion by 2029
Read MoreIndonesia IVD Market Worth $1.11 Billion by 2029
Read MoreMedical Waste Management Market Worth $17.02 billion by 2030
Read MoreEmpty Capsules Market Worth $4.47 Billion by 2029
Read MoreClear Aligners Market to be worth $18.8 Billion by 2030
Read MoreHLA Typing Market Worth $1.9 Billion by 2029
Read MoreReal-world Data Market Worth $1.66 billion by 2029
Read MoreTrack and Trace Solutions Market Worth $27.27 billion by 2029
Read MoreSurface Disinfectant Market Worth $9.52 Billion by 2029
Read MoreElectronic Lab Notebook Market Worth $787.7 million by 2029
Read MoreRapid Diagnostics Market to be Worth $22.65 Billion By 2031
Read MorePlasma Therapy Market Worth $882.5 Million by 2028
Read MorePeripheral Vascular Devices Market Worth $12.02 Billion by 2028
Read MoreBiomaterials Market to Reach 128.7 Billion USD by 2023
Read MoreVaccine Storage Equipment Market Worth $1.83 billion by 2027
Read MorePlasma Fractionation Market Worth $46.9 Billion by 2029
Read MoreHome Healthcare Market to be Worth $514.5 Billion by 2030
Read MoreCardiac Pacemaker Devices Market Worth $4.34 Billion by 2028
Read MoreEuropean Laboratory Informatics Market Worth $1,084.3 Million By 2024
Read MoreCompetent Cells Market Worth 2,318.6 Million USD By 2023
Read MoreCancer Immunotherapy Market to be Worth $267.2 Billion by 2030
Read MoreMultimodal Imaging Market Worth $1.6 Billion By 2024
Read MorePulse Lavage Market to be Worth $661.1 Million by 2030
Read MoreMedical Cooling Systems Market Worth $2.8 Billion By 2024
Read MoreTissue Diagnostics Market Worth $8.52 Billion by 2029
Read MoreEndoscopy Equipment Market Worth $59.8 Billion by 2029
Read MoreAfrican Forensic DNA Testing Market Worth $136.3 Million by 2025
Read MoreClinical Trial Supplies Market to be Worth $5.59 Billion by 2031
Read MoreInfection Control Market Worth $58.2 Billion by 2027
Read MoreSleep Apnea Devices Market Worth $12.9 billion by 2027
Read MoreMedical 3D Printing Market To Reach $983.2 Million By 2020
Read MoreGenomics Market to be Worth $70.52 Billion by 2031
Read MoreAnalytical Standards Market Worth $2.66 Billion By 2027
Read MoreTelehealth Market Worth $539.73 Billion by 2029
Read MoreCell Culture Market Worth $48.63 Billion by 2029
Read MoreAntimicrobial Coatings Market to be Worth $12.41 Billion by 2031
Read MoreFlow Cytometry Market Worth $6.4 Billion by 2027
Read MoreMedical Aesthetics Market Worth $29.43 billion by 2029
Read MoreOligonucleotide Synthesis Market Worth $3.9 Billion by 2025
Read MoreIn Vitro Diagnostics Market to be Worth $116.28 Billion by 2031
Read MoreDental Implants Market Worth $6.52 Billion by 2029
Read MoreActive Implantable Devices Market Worth 24.02 Billion USD By 2022
Read MoreVentilators Market to be Worth $13.23 Billion by 2031
Read MoreDialysis Market to be Worth $36.6 Billion by 2031
Read MorePlasmapheresis Market to be Worth $2.55 Billion by 2030
Read MoreDiabetes Care Devices Market Worth $31.9 Billion by 2028
Read MoreClinical Genomics Market Worth 879.0 Million USD By 2023
Read MoreIVD Quality Control Market to be Worth $2.28 Billion by 2031
Read MoreLaboratory Informatics Market Worth $6.1 Billion by 2030
Read MoreChromatography Data Systems Market to be Worth $1.7 billion by 2030
Read MoreBone Growth Stimulators Market Worth $1.94 Billion by 2030
Read MoreDigital Diabetes Market worth $12.03 billion by 2025
Read MoreTrocars Market Worth $968.5 Million by 2024
Read MoreHealthcare Virtual Assistant Market Worth $1.76 Billion By 2025
Read MoreEurope Hospital Beds Market to be Worth $2.09 Billion by 2030
Read MoreImmunoassay Market Worth $46.49 Billion by 2028
Read MoreHospital Beds Market Worth $ 6.66 Billion by 2030
Read MoreUrinalysis Market Worth $2.19 billion by 2027
Read MoreMedical Image Management Market Worth $7.22 billion by 2030
Read MoreBreast Imaging Market Worth $7.08 Billion by 2027
Read MoreVNA & PACS Market to be Worth $6.50 Billion by 2031
Read More